Abstract
[...]an overview of trials--including recent meta-analyses--suggests that BNP- or NT-proBNP-guided therapy may reduce mortality, especially in younger patients. [...]it may have a role as an adjunct to standard of care, especially in younger patients, particularly those with systolic dysfunction. [...]data are needed from more robust, adequately powered trials with hard clinical outcomes and from a meta-analysis utilizing individual patient data (rather than summary grouped data) before guidelines can confidently endorse a biomarker-guided strategy.